HELLO, THEE WILL NOT BE A MAILOUT TOMORROW, THURSDAY.
FROM HOPKINS CITATIONS”
1. DOD Prioritizing COVID-19 Vaccinations to Those Deployed The Defense Department is rapidly administering COVID-19 vaccines in a tiered priority process to service members, DOD contractors and civilians and their families who are stationed overseas and who wish to have them, said DOD health leaders. Of all doses the department has received, 14% are set aside for overseas locations. (DOD, 4/8/2021)
2. (REPEAT) Innovation Challenge Seeks to Solve a Common Hurdle in Curbing Coronavirus Spread: Mask Design Last week BARDA launched a contest called the Mask Innovation Challenge: Building Tomorrow’s Mask to design effective, comfortable masks for the public. They’re offering $500,000 in cash prizes because we’re certain American ingenuity can design and build better masks that people are more willing to wear and trust. In the first phase, up to 10 winning ideas will split $100,000 for winning design ideas. Ideas are due by 5 p.m. ET, April 21, 2021. In the second phase, up to five winning prototypes will split $400,000. (PHE, 4/8/2021)
The researchers note that the increased risk of B.1.1.7[European] infection among partially vaccinated individuals suggests that delaying the second dose, as is the policy in some countries, could delay full protection against this VOC. Conversely, the B.1.351 variant [S. African] is relatively rare in Israel, so there are less data available on these infections.
J. Harris: I can’t find a clear summary. I believe what they are saying is that in vaccinated people, they found a higher percentage of variants than were found in unvaccinated Covid positive subjects, which is not surprising. I’ll follow this up. This information is from a preprint. TAKE BOTH DOSES OF YOUR VACCINE.
FROM MY NORWEGIAN HOUSEKEEPER:
(J. Harris: Covid causes more blood clots that the vaccinations do.)
UPDATE FROM HOPKINS:
Updated NIH COVID-19 Treatment Guidelines Recommend REGEN-COV for Non-hospitalized, High Risk Patients (Homeland Preparedness News)
A mix of casirivimab and imdevimab, Regeneron Pharmaceuticals Inc.’s REGEN-COV, is now strongly recommended by the National Institutes of Health (NIH) for high risk COVID-19 patients that are non-hospitalized. The drug was given a strong rate based on randomized trials, which involved more than 4,500 outpatients. That data showed REGEN-COV significantly reduced the risk of hospitalization or death by 70 percent when compared to placebo.
LAST BUT NOT LEASED:
Quantum mechanics- the dreams stuff is made of
I just got lost in thought. It was unfamiliar territory.
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.